Butterfly Network to Participate at the TD Cowen 45th Annual Health Care Conference on March 3, 2025
NEW YORK & BURLINGTON, Mass.--(BUSINESS WIRE)--Feb 21, 2025--
Butterfly Network, Inc. (NYSE: BFLY) ('Butterfly') a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that it will present and host one-on-one investor meetings at the TD Cowen 45th Annual Health Care Conference in Boston on March 3, 2025. Heather Getz, Executive Vice President & Chief Financial and Operations Officer will host one-on-one meetings and will present a business overview at 1:10pm EST.
A webcast of the presentation will be available in the Events & Presentations section of the Butterfly investor website.
About Butterfly Network
Butterfly Network, Inc. (NYSE: BFLY) is a healthcare company driving a digital revolution in medical imaging with its proprietary Ultrasound-on-Chip™ semiconductor technology and ultrasound software solutions. In 2018, Butterfly launched the world's first handheld, single-probe, whole-body ultrasound system, Butterfly iQ. The iQ+ followed in 2020, and the iQ3 in 2024, each with improved processing power and performance by leveraging Moore's Law. The iQ3 earned Best Medical Technology at the 2024 Prix Galien USA Awards, a prestigious honor and one of the highest accolades in healthcare. Butterfly's innovations have also been recognized by Fierce 50, TIME's Best Inventions and Fast Company's World Changing Ideas, among other achievements.
Butterfly Network, Inc. (NYSE: BFLY) is a healthcare company driving a digital revolution in medical imaging with its proprietary Ultrasound-on-Chip™ semiconductor technology and ultrasound software solutions. In 2018, Butterfly launched the world's first handheld, single-probe, whole-body ultrasound system, Butterfly iQ. The iQ+ followed in 2020, and the iQ3 in 2024, each with improved processing power and performance by leveraging Moore's Law. The iQ3 earned Best Medical Technology at the 2024 Prix Galien USA Awards, a prestigious honor and one of the highest accolades in healthcare. Butterfly's innovations have also been recognized by Fierce 50, TIME's Best Inventions and Fast Company's World Changing Ideas, among other achievements.
Butterfly combines advanced hardware, intelligent software, AI, services, and education to drive adoption of affordable, accessible imaging. Clinical publications demonstrate that its handheld ultrasound probes paired with Compass™ enterprise workflow software, can help hospital systems improve care workflows, reduce costs, and enhance provider economics. With a cloud-based solution that enables care anywhere through next-generation mobility, Butterfly aims to democratize healthcare by addressing critical global healthcare challenges. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: .
Heather Getz
Chief Financial and Operations Officers, Butterfly
[email protected] Halper
LifeSci Advisors (IR Representative)
646-876-6455
SOURCE: Butterfly Network, Inc.
Copyright Business Wire 2025.
PUB: 02/21/2025 08:05 AM/DISC: 02/21/2025 08:04 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Why ImmunityBio, Inc. (IBRX) Skyrocketed Today
We recently published a list of . In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against other Wednesday's best-performing stocks. ImmunityBio extended its winning streak to a fifth consecutive day on Wednesday, jumping 8.1 percent to finish at $2.93 apiece as investors cheered the Food and Drug Administration's (FDA) green light for the company to expand the access of its Anktiva treatment to patients with solid tumors. According to ImmunityBio, Inc. (NASDAQ:IBRX), it was granted by the FDA to treat lymphopenia in adult patients with refractory or relapsed solid tumors. 'Lymphopenia has long been recognized as a major driver and predictor of early mortality in cancer—yet until now, it has remained unaddressed,' said ImmunityBio, Inc. (NASDAQ:IBRX) founder and Executive Chairman Patrick Soon-Shiong. A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents. 'This FDA authorization allows all patients with solid tumors suffering from immune collapse following first-line therapy of chemo, radiation, or immunotherapy to access ANKTIVA. The survival benefit we observed at ASCO 2025 in 3rd to 6th line advanced metastatic pancreatic cancer confirms that restoring lymphocyte levels, rather than depleting them, can change the course of disease.' Following the announcement, the company earned a 'buy' recommendation and a price target of $8 from investment firm HC Wainwright. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
3 of the Cheapest Artificial Intelligence Stocks to Buy Right Now
The tech companies listed here are all investing heavily in artificial intelligence. Their valuations are modest when factoring in their long-term growth opportunities. 10 stocks we like better than Alphabet › Want to add some promising artificial intelligence (AI) stocks to your portfolio, without paying an obscene price? While many stocks are trading at inflated valuations, there are still many good options out there to consider, which can deliver strong returns for your portfolio. Three AI stocks that possess a lot of upside and are among the cheapest options for growth investors to buy right now are Alphabet (NASDAQ: GOOG)(NASDAQ: GOOGL), Alibaba Group Holdings (NYSE: BABA), and Advanced Micro Devices (NASDAQ: AMD). Here's why it may not be too late to invest in these stocks. Shares of Alphabet are down around 11% this year as investors are concerned about antitrust issues and a possible breakup of the business, or at the very least, changes to its core operations. But there's a lot to like about the business. The company is planning to spend $75 billion on capital expenditures this year as it works on creating next-generation technologies. Alphabet's core business also still looks solid. Investors shouldn't forget that while ChatGPT has been around for multiple years now, Alphabet's ad business still remains strong -- the popular chatbot hasn't made a big dent in the company's earnings. During the first three months of this year, Alphabet's revenue totaled $90.2 billion, which came in better than expectations and rose by 12% year over year. Earlier this year, it announced plans to acquire cybersecurity company Wiz for $32 billion. It's a great asset to add into the mix to enhance its growth prospects even further. Alphabet already has its own chatbot, Gemini, a robotaxi in Waymo, plus its amazingly popular core assets -- YouTube and Google Search. With an abundance of growth potential, Alphabet looks like a steal of a deal, trading at just 19 times its trailing earnings. If you're looking for more of a discounted AI stock to buy, then Alibaba may be to your liking. At 15 times its trailing earnings, its valuation is low and it compensates investors for the risk that comes with buying shares of this Chinese company. Alibaba recently released its latest AI model, Qwen3, which uses "hybrid reasoning" that can balance deep-thinking tasks alongside more standardized questions where speed is important. Tech giant Apple has partnered with Alibaba and is integrating the Chinese company's AI in its new iPhones, which is a great testament to the effectiveness and potential for Alibaba's AI in the future. During the first three months of the year, Alibaba says its AI-related product revenue grew by triple digits for a seventh straight quarter. Although its total revenue grew by just 7% to $32.6 billion, Alibaba's vast business (which includes online retail, cloud, and logistics) is why its AI revenue isn't standing out more. But there's potential for it to be a huge growth catalyst for years to come. Investing in a top chipmaker is another good way to gain a position in AI. Advanced Micro Devices, also known as AMD, is one of Nvidia's main rivals. The stock doesn't look terribly cheap as it's trading at a price-to-earnings multiple of 80. But when you look at its price/earnings-to-growth (PEG) multiple, which factors in how much growth analysts are expecting over the coming years, that ratio is at less than 0.6. For growth investors, anything less than one is a good multiple for PEG, and AMD is well below that level. The company's business has been doing well recently with AMD's revenue rising by 36% for the period ending March 29, totaling $7.4 billion. Its new AI chips are proving to be in high demand, and if the company can keep on this pace, then there could be a lot of upside for AMD down the road. CEO Lisa Su has previously forecast that its AI chip business could bring in tens of billions in potential revenue in the future. And if those projections turn out true, then this could indeed become one of the best AI stocks to buy right now. Before you buy stock in Alphabet, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Alphabet wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices, Alphabet, Apple, and Nvidia. The Motley Fool recommends Alibaba Group. The Motley Fool has a disclosure policy. 3 of the Cheapest Artificial Intelligence Stocks to Buy Right Now was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
Why STMicroelectronics N.V. (STM) Skyrocketed Today
We recently published a list of . In this article, we are going to take a look at where STMicroelectronics N.V. (NYSE:STM) stands against other Wednesday's best-performing stocks. STMicroelectronics jumped by 10.67 percent on Wednesday to end at $28.41 apiece following optimism that it would hit its revenue guidance for the second quarter of the year amid the increasing demand for its semiconductors. For the current quarter, STMicroelectronics N.V. (NYSE:STM) is forecasting to book $2.71 billion in revenues, or 7.7 percent higher than the first quarter of the year. A worker assembling the inner circuitry of a semiconductor product. Additionally, STMicroelectronics N.V. (NYSE:STM) is continuing its workforce reduction initiative, with a total of 5,000 employees expected to be laid off over the next three years. Of the total, 2,800 have already been let go earlier this year. In the first quarter of the year, STMicroelectronics N.V. (NYSE:STM) reported an 89.1 percent drop in net income to $56 million from $513 million in the same period last year. Revenues also dropped by 27.3 percent to $2.5 billion from $3.46 billion year-on-year. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
